At MNGI Digestive Health, quality care and cancer prevention are central to our mission. One key measure of colonoscopy quality is the Adenoma Detection Rate (ADR), which tracks how often precancerous polyps are found during a procedure. A higher ADR means a greater opportunity to prevent colorectal cancer before it starts.
National leaders in gastroenterology, including the American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy, recommend a benchmark ADR of at least 35%. Meeting or exceeding this benchmark is associated with a meaningful reduction in the risk of developing colorectal cancer after colonoscopy.
We are proud to share that MNGI’s 2025 average ADR reached 70.2%, double the national recommendation. This achievement reflects our physicians’ dedication to careful screening, early detection, and delivering the highest standard of preventive care.
Every adenoma detected and removed is an opportunity to stop cancer before it develops. That’s why we continuously monitor quality measures and follow evidence-based guidelines to ensure patients receive safe, effective, and thorough care.
At MNGI, exceeding quality standards isn’t the exception. Our team remains committed to providing expert, patient-centered care and helping our community stay proactive about digestive health. To learn more about ADR and our quality outcomes, visit the Quality & Outcomes section of our About Us page.
